37 results about "Neoplastic cell" patented technology

The present disclosure provides T cell modulatory polypeptide-epitope conjugates (T-Cell-MP-epitope conjugates) comprising a chemical conjugation site at which a coronavirus peptide epitope is covalently attached and at least one immunomodulatory polypeptide sequence. The T-Cell-MP-epitope conjugates are useful for modulating the activity (e.g., increasing proliferation or cytotoxic activity) of T-cells specific to the coronavirus peptide epitope in an epitope selective / specific manner, and accordingly, for treating individuals with a coronavirus infection including long COVID. Alternatively, when the T-Cell-MP-epitope conjugate is redirected to a neoplastic cell by a targeting sequence, the redirected T-Cell-MP-epitope conjugate may be used to treat neoplasms including various cancers.

Provided are ATF5 peptides having a truncated ATF5 leucine zipper region and, optionally, a cell-penetrating region, compositions comprising the ATF5 peptides, and methods of inhibiting proliferation of and promoting cytotoxicity in a neoplastic cell using the ATF5 peptides.

Tumor glycocalyx may be regarded as a glycan “canopy” above the tumor plasma membrane. Disclosed are methods of treating a neoplastic malignant cell cancer wherein the neoplastic malignant cancer cell has a malignant glycocalyx B. Also disclosed are methods of inducing apoptosis of one or more neoplastic malignant cells and methods of increasing a subject's responsiveness to an immunotherapy wherein the neoplastic malignant cancer cell has a malignant glycocalyx B.

Provided are BCL9 mimetic peptides having a modified a-helical homology domain-2 (HD2) region and, optionally, a cell-penetrating region, compositions comprising the BCL9 mimetic peptides, and methods of inhibiting proliferation of and / or promoting cytotoxicity in a neoplastic cell using the BCL9 mimetic peptides.

The present invention relates to the fields of medicine, cell biology, molecular biology and genetics. In particular, the present invention provides methods to isolate and purify microvesicles from cell culture supernatants and biological fluids. The present invention also provides pharmaceutical compositions of microvesicles to promote or enhance wound healing, stimulate tissue regeneration, remodel scarred tissue, modulate immune reactions, alter neoplastic cell growth and / or mobility, or alter normal cell growth and / or mobility. The present invention also provides compositions of microvesicles to be used as diagnostic reagents, and methods to prepare the compositions of microvesicles.

Methods are provided for assaying neoplastic cells and / or neoplasia-related cells. Aspects of the methods involve detecting heterogeneity, per cell programmed-death ligand 1 (PD-L1) expression, and / or proliferation of neoplasia and / or neoplasia-related cells. Aspects of the methods include cytometrically assaying a labeled cell suspension to quantify per cell heterogeneity, per cell PD-L1 expression, proliferation, and / or other parameters to detect whether a neoplastic cell is present in the neoplasia sample. Aspects of the provided methods also include treating a subject based on the outcome of such an assay. In addition, kits that find use in practicing the subject methods are also provided.

The present disclosure relates to fused ring compounds, as well as conjugates and uses thereof. The compounds and conjugates of the present disclosure have excellent tumor cell inhibitory activity, stability, and efficacy in animals. [Summary] Figure 1

Methods are provided for the treatment of cancer or neoplastic diseases and the like, by administering 4-[2-(4-amino-piperidin-1-yl)-5-(3-fluoro-4-methoxy-phenyl)-1-methyl-6-oxo-1,6-dihydro-pyrimidin-4-yl]-2-fluoro- benzonitrile (compound of Formula (I)) or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising compounds useful for the inhibition of lysine specific demethylase-1 (LSD-1) to patients in need thereof. Methods are further drawn to administering compositions described herein to patients having neoplastic cells that express RCOR2.

The disclosure provides agents that sensitize neoplastic cells through glycosylation by a glycosyltransferase. In the mechanism of cytotoxicity discussed herein, compounds become glycosylated resulting in comitant cytotoxicity. Exemplary compounds include: Compound 1 (BRD9645), Compound 2 ((R112), Compound 3 (Tioxolone), Compound 4 (Baf A1).

The present invention relates to the fields of medicine, cell biology, molecular biology and genetics. In particular, the present invention provides methods to isolate and purify microvesicles from cell culture supernatants and biological fluids. The present invention also provides pharmaceutical compositions of microvesicles to promote or enhance wound healing, stimulate tissue regeneration, remodel scarred tissue, modulate immune reactions, alter neoplastic cell growth and / or mobility, or alter normal cell growth and / or mobility. The present invention also provides compositions of microvesicles to be used as diagnostic reagents, and methods to prepare the compositions of microvesicles.

Macrocyclic chelators for chelation of alpha-emitting radiometal ions, such as actinium-225 are provided. Also provided are radiometal complexes containing an alpha-emitting radiometal ion bound to the macrocyclic chelator via coordinate bonding, and radioimmunoconjugates containing the radiometal complexes covalently linked to a targeting ligand, such as an antibody or antigen binding fragment thereof. The radioimmunoconjugates can be produced by click chemistry reactions. Methods of using the radiocomplexes and radioimmunoconjugates for selectively targeting neoplastic cells for radiotherapy and for treating neoplastic diseases and disorders are also described.

Provided are ATF5 peptides having a truncated ATF5 leucine zipper region and. optionally, a cell-penetrating region, compositions comprising the ATF5 peptides, and methods of inhibiting proliferation of and promoting cytotoxicity in a neoplastic cell using the ATF5 peptides.

Macrocyclic chelating agents (I) are provided for the chelation of alpha-emitting radiometal ions, such as actinium-225. Radiometal complexes containing an alpha-emitting radiometal ion linked to the macrocyclic chelating agent via a coordinate linkage are also provided, as are radioimmunoconjugates containing the radiometal complexes covalently linked to a targeting ligand, such as an antibody or an antigen-binding fragment. The radioimmunoconjugates can be produced by click chemistry reactions. Methods for using the radiocomplexes and radioimmunoconjugates for the selective targeting of neoplastic cells in radiotherapy and for the treatment of neoplastic diseases and disorders are also described.

The present disclosure provides a pharmaceutical association comprising at least one growth factor receptor-binding compound, which activates at least one growth factor receptor of a neoplastic cell, and at least one adhesion protein inhibitor which inhibits at least one transmembrane cell adhesion protein of said neoplastic cell.

The present invention provides a technology useful for predicting prognosis in a follicular lymphoma patient. The present invention is a method for quantifying neoplastic follicular regulatory T cells and neoplastic follicular cytotoxic T cells in T cells collected from a subject, in order to determine the prognosis of follicular lymphoma. The method comprises: a flow cytometry step in which neoplastic follicular regulatory T cells and neoplastic follicular cytotoxic T cells in T cells collected from a subject are detected and counted with flow cytometry using an anti-CD4 antibody, an anti-CD8 antibody, an anti-PD-1 antibody, an anti-CD25 antibody, and an anti-TIM-3 antibody; or a multiplex immunostaining step in which neoplastic follicular regulatory T cells and neoplastic follicular cytotoxic T cells in T cells collected from a subject are detected and counted with multiplex immunostaining using an anti-CD4 antibody, an anti-CD8 antibody, an anti-PD -1 antibody, an anti-FOXP3 antibody, an anti-TCF-1 antibody, and an anti-Granzyme K antibody.

The utility model discloses a colorectal cancer micro tumor cell culture device which comprises a culture dish and a sealing cover, the sealing cover covers and presses the top of the culture dish, the outer walls of the culture dish and the sealing cover are sleeved with two semi-arc-shaped cladding plates, the interiors of the two semi-arc-shaped cladding plates are of a cavity structure, and the two semi-arc-shaped cladding plates are arranged in the cavity structure. And the internal cavities of the two semi-arc cladding plates are filled with purified water. According to the utility model, purified water filled in the semi-arc-shaped cladding plate is used as a high-specific-heat-capacity heating medium, and a closed-loop temperature control system constructed by the electric heating wire and the top thermometer is combined, so that the temperature of the inner cavity of the culture dish can be continuously maintained after the culture dish is separated from an incubator environment, and the interference of external environment temperature fluctuation is effectively resisted; the method is especially suitable for cross-laboratory cooperation or in-situ detection scenes requiring frequent sample transfer; through the collaborative design of the arc-shaped through groove and temperature control, the proper temperature can be ensured while the colorectal cancer cells are observed, and temperature loss is avoided.

The present disclosure provides compositions for inhibiting interaction of Siglec-5 with its cognate ligand on cancer cells and their use as checkpoint inhibitors in the treatment of neoplastic disorders. A method for the treatment and / or prevention of a cancer that expresses a Siglec-5 ligand in a subject is provided comprising administering to the subject a molecule that inhibits the interaction between Siglec-5 and a Siglec-5 ligand expressed on the cancer cell. In some aspects, the subject is identified as having a cancer expressing a Siglec-5 ligand. Preferably, the molecule is a monoclonal antibody against Siglec-5.

The present invention comprises synthetic peptides derived from the venom of the H. junceus scorpion with anti-metastatic properties, as well as compositions of synthetic peptides derived from the venom of the H. junceus scorpion and its variants, which are obtained from recombinant or synthesis techniques, with anti-metastatic properties and which are effective against tumour cells or small cell lung cancer cells.

The invention pertains to the technical fields of pharmaceutical sciences, immunology, diagnosis and / or treatment of cancer. Specifically, the invention relates to peptides derived from the C-terminal portion of the tick amblyomin-X protein, said peptides being intended for targeting or promoting the internalization of molecular entities into the intracellular domain of eukaryotic or neoplastic cells. The invention also relates to the use of said peptides for modifying other pharmaceutically active ingredients, to a pharmaceutical composition comprising said peptides and to a method of diagnosis, prognosis and / or treatment of cancer or other cell-altering conditions.

Control compositions and methods of making the same are provided. Aspects of the control compositions include a first white blood cellular component including one or more positive control markers for white blood cells; a second cellular component including one or more positive control markers for hematopoietic stem / progenitor cells; and a third cellular component including one or more positive control markers for neoplastic cells, wherein the first white blood cellular component, the second cellular component, and third cellular component are fixed. Also provided are methods for using the control compositions as positive controls, e.g., in a flow cytometric assay, as well as kits for practicing the subject methods.

Pharmaceutical compositions comprising active doses of EGCG or a combination of EGCG and quinine or EGCG and a zinc salt for topical treatment of dysplastic or neoplastic cells in mucosal or cutaneous epithelial cells, including cervical intra-epithelial neoplasia, and methods for their use to induce regression of mucosal dysplasia are provided.

Embodiments of the invention are directed to methods of determining the prognosis of a breast cancer patient by evaluating the activity of the glucocorticoid receptor in tumor cells. Other embodiment include methods of treating breast cancer cells, particularly, chemo-resistant cells, with a glucocorticoid receptor antagonist and an anticancer agent or compound.

Compositions and methods for treating cancer are provided. In particular, the compositions comprise an encapsulated CD1d-restricted invariant Natural Killer T (iNKT) cell antigen, such as glycosphingolipid, for example, α-galactosylceramide. Methods of administering the compositions in combination with a therapy that induces the death of neoplastic cells in the subject are provided.

An indole alkaloid, specifically the alkaloid (3S,3aR,8aS)-3-butyl-5-hydroxy-3,3a,8a-trimethyl-3,3a,8,8a-tetrahydro-2H-furo[2,3-b]indole-2-one, with the generic name Andranone, as an antineoplastic agent against neoplastic cells of colon cancer, breast cancer, leukaemia, central nervous system cancer, prostate cancer, lung cancer and cervical cancer.

The invention discloses an integrated microfluidic biosensor chip based on a micro-column array D-type optical fiber, and belongs to the field of biological detection. The integrated microfluidic biosensing chip based on the micro-column array D-type optical fiber comprises a fiber-based micro-column array D-type sensing optical fiber, the side edge polishing surface of the fiber-based micro-column array D-type sensing optical fiber is provided with a periodic micro-column array; the surface of the microcolumn array is sequentially coated with a sensibilization layer and a specific modification layer; the raw material of the sensitization layer comprises a sensitization material, the sensitization material comprises an MXene material and / or a metal nano material, and the raw material of the specific modification layer comprises a biological aptamer material. The micro-column array structure can be used as a cell capture enhancement interface to form a large number of capture sites, so that the contact area between cells and the surface of the chip is increased, and the cell capture efficiency is improved. The intensity of an evanescent field of the optical fiber can be greatly enhanced by the sensibilization layer, specific recognition is realized by the biological aptamer material, and good sensitivity and detection precision can also be realized for extremely-low-concentration circulating tumor cells.

Aspects of the disclosure include methods for treating a myeloproliferative neoplasm. Methods according to certain embodiments include co-administering to a subject a Janus kinase (JAK) inhibitor and a telomerase inhibitor comprising an oligonucleotide and a lipid moiety linked to the 5′ and / or 3′ end of the oligonucleotide. Methods for inducing apoptosis of a myeloproliferative neoplasm cell by contacting the cell with an amount of a JAK inhibitor and a telomerase inhibitor sufficient to induce apoptosis are also described. Compositions having a JAK inhibitor and a telomerase inhibitor for practicing the subject methods are also provided.

A dendritic cell (DC)-targeting M13 phage vaccine platform is provided herewith, where spy-tagged neoantigens can be attached to the phage surface with spy-catchers. By expressing DC-targeting peptides and spy-catchers as foreign antigens on the phage surface, its therapeutic and antigenic properties can be enhanced to combat solid cancers. SLS-spy catcher phage (SCP), with or without neoantigen conjugation, significantly repressed tumour growth by boosting systemic anti-tumour immunity and increasing intratumoral infiltration of both innate and adaptive immune cells. Intratumoral administration of SCP also hugely reduced PDL1 expression on tumour cells, making them more susceptible to immune attacks. Additionally, SCP administration restricted the size of blood vessels inside the tumour mass, suggesting multiple factors contribute to restrict tumour growth.

Soluble multispecific protein that binds a target peptide MHC complex on a target cell and a surface receptor on an immune cell, incorporating a half life extending region (eg., Fc region) attached via a cleavable linker. Inclusion in the linker of a substrate sequence for a protease specific to the tumour microenvironment selectively releases an active portion of the protein from the half life extending region at the tumour site. Release of the active complex increases its potency for mediating T cell signalling at an immune synapse with tumour cells presenting the target pMHC.

Dominant negative forms of CEBPB and CEBPD, and cell-penetrating forms thereof are described. Methods for using the dominant negative forms of CEBPB and CEBPD proteins, and cell-penetrating forms thereof, for decreasing viability of neoplastic cells and treating cancer in a subject are also described.